CY2540B1 - Vaccine against mumps containing a jeryl-lynn virus strain - Google Patents

Vaccine against mumps containing a jeryl-lynn virus strain

Info

Publication number
CY2540B1
CY2540B1 CY0500054A CY0500054A CY2540B1 CY 2540 B1 CY2540 B1 CY 2540B1 CY 0500054 A CY0500054 A CY 0500054A CY 0500054 A CY0500054 A CY 0500054A CY 2540 B1 CY2540 B1 CY 2540B1
Authority
CY
Cyprus
Prior art keywords
jeryl
virus strain
vaccine against
mumps
lynn
Prior art date
Application number
CY0500054A
Other languages
English (en)
Inventor
Nigel Maurice Harford
B D A Colau
J Didelez
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939323820A external-priority patent/GB9323820D0/en
Priority claimed from GB9406480A external-priority patent/GB9406480D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CY2540B1 publication Critical patent/CY2540B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0015Combination vaccines based on measles-mumps-rubella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165Mumps or measles virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18761Methods of inactivation or attenuation
    • C12N2760/18762Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36211Rubivirus, e.g. rubella virus
    • C12N2770/36234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY0500054A 1993-11-19 2005-09-30 Vaccine against mumps containing a jeryl-lynn virus strain CY2540B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323820A GB9323820D0 (en) 1993-11-19 1993-11-19 Vaccine
GB9406480A GB9406480D0 (en) 1994-03-31 1994-03-31 Vaccine

Publications (1)

Publication Number Publication Date
CY2540B1 true CY2540B1 (en) 2006-06-28

Family

ID=26303889

Family Applications (2)

Application Number Title Priority Date Filing Date
CY0500054A CY2540B1 (en) 1993-11-19 2005-09-30 Vaccine against mumps containing a jeryl-lynn virus strain
CY2008005C CY2008005I2 (el) 1993-11-19 2008-02-19 Εμβολιο κατα της παρωτιτιδας που περιεχει στελεχος ιου jeryl-lynn

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2008005C CY2008005I2 (el) 1993-11-19 2008-02-19 Εμβολιο κατα της παρωτιτιδας που περιεχει στελεχος ιου jeryl-lynn

Country Status (20)

Country Link
US (4) US6024962A (xx)
EP (2) EP1484391A1 (xx)
JP (1) JPH09504954A (xx)
KR (1) KR100362051B1 (xx)
CN (2) CN101948816A (xx)
AT (1) ATE266090T1 (xx)
AU (1) AU687922B2 (xx)
CA (1) CA2176929C (xx)
CY (2) CY2540B1 (xx)
DE (3) DE122007000003I2 (xx)
DK (1) DK0729509T3 (xx)
ES (1) ES2219658T3 (xx)
HK (1) HK1012421A1 (xx)
LU (1) LU91458I2 (xx)
NL (1) NL300336I2 (xx)
NZ (1) NZ276102A (xx)
PT (1) PT729509E (xx)
SG (1) SG52780A1 (xx)
SI (1) SI0729509T1 (xx)
WO (1) WO1995014083A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176929C (en) 1993-11-19 2002-04-30 Nigel Maurice Harford Vaccine against mumps containing a jeryl-lynn virus strain
JP2003506039A (ja) * 1999-08-02 2003-02-18 ワイス cDNAからの流行性耳下腺炎ウイルスのレスキュー
WO2016157208A1 (en) * 2015-03-27 2016-10-06 Cadila Healthcare Limited Recombinant mumps virus jeryl lynn 2 based vaccine
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
CN114457046A (zh) * 2022-02-16 2022-05-10 科兴(大连)疫苗技术有限公司 一种稀释法传代纯化腮腺炎病毒的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555149A (en) 1968-07-05 1971-01-12 Merck & Co Inc Mumps vaccine and its preparation
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
JP3026029B2 (ja) * 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
CA2176929C (en) 1993-11-19 2002-04-30 Nigel Maurice Harford Vaccine against mumps containing a jeryl-lynn virus strain

Also Published As

Publication number Publication date
NZ276102A (en) 1998-04-27
KR960705919A (ko) 1996-11-08
CN101948816A (zh) 2011-01-19
DE122007000003I1 (de) 2007-05-24
ES2219658T3 (es) 2004-12-01
SI0729509T1 (en) 2004-08-31
US6656476B2 (en) 2003-12-02
ATE266090T1 (de) 2004-05-15
US6024962A (en) 2000-02-15
NL300336I1 (nl) 2008-04-01
US20020018784A1 (en) 2002-02-14
US20030095984A1 (en) 2003-05-22
CY2008005I1 (el) 2012-01-25
EP0729509B1 (en) 2004-05-06
SG52780A1 (en) 1998-09-28
JPH09504954A (ja) 1997-05-20
HK1012421A1 (en) 1999-07-30
PT729509E (pt) 2004-09-30
EP0729509A1 (en) 1996-09-04
KR100362051B1 (ko) 2003-04-11
AU687922B2 (en) 1998-03-05
WO1995014083A1 (en) 1995-05-26
EP1484391A1 (en) 2004-12-08
CA2176929C (en) 2002-04-30
US6899884B2 (en) 2005-05-31
US20040120969A1 (en) 2004-06-24
DE69433760T2 (de) 2005-05-12
DE122007000003I2 (de) 2011-01-13
DE69433760D1 (de) 2004-06-09
NL300336I2 (nl) 2009-01-05
CN1150819A (zh) 1997-05-28
AU8144194A (en) 1995-06-06
CY2008005I2 (el) 2018-01-10
DK0729509T3 (da) 2004-08-16
LU91458I2 (fr) 2008-08-25
CA2176929A1 (en) 1995-05-26

Similar Documents

Publication Publication Date Title
EP0584348A4 (en) Genetic vaccine for immunodeficiency viruses
CA2123612A1 (en) Hybrid protein between cs from plasmodium and h bsag
PL317234A1 (en) Vaccines against papilloma virus
BG101995A (en) Saponin and sterol-containing vaccines
AU3636189A (en) Hiv-2 virus variants
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
GR3035135T3 (en) Poultry vaccine containing infections bronchitis virus serotype 4/91.
AU580059B2 (en) Vaccine against rabies and preparation process thereof
EP0467700A3 (en) Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties
CY2540B1 (en) Vaccine against mumps containing a jeryl-lynn virus strain
EP0888777A3 (en) Recombinant bovine herpesvirus type 1 polyptpetides and vaccines
NZ238833A (en) Equine herpesvirus-4 gh or gc polypeptides, nucleic acids encoding them and vaccines therefrom
WO1995012682A3 (en) Viral vector with bovine viral diarrhea virus (bvdv) antigens
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
ZA915626B (en) Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties